News
February 20, 2013
Read Vitae CEO Jeff Hatfield's views on the Life Sciences market in the Grant Thornton Life Sceinces spotlight.
October 8, 2012
Watch Vitae CEO Jeff Hatfield discuss the challenges facing private biotech companies in the IPO market during his appearance on BioCentury TV.
Sept 6, 2012
Vitae Pharmaceuticals to present the poster, "VTP-4, a Potent and Selective LXRß Modulator for Potential Treatment of Atherosclerosis" at the Frontiers in Lipid Biology Meeting in Banff, AB.
January 19, 2012
Vitae Pharmaceuticals secures $15M in debt financing to support the progress of their discovery pipeline.
January 5, 2012
Vitae Pharmaceuticals to present at the 30th Annual JP Morgan Healthcare Conference in San Francisco on January 12, 2012.
November 14, 2011
Vitae Pharmaceuticals highlights VTP-27999 data in two late breaker poster presentations at the American Society of Nephrology's Kidney Week 2011.
October 5, 2011
Vitae President and CEO Jeff Hatfield has been elected to the Board of Directors of the Biotechnolog Industry Organization.
April 29, 2011
Vitae Pharmaceuticals is named one of the Top Ten Best Places to Work by The Scientist magazine.
December 2, 2010
Vitae Pharmaceuticals is named one of the Best Places to Work in Pennsylvania.
September 29, 2010
Vitae Pharmaceuticals' President and CEO Jeffrey Hatfield Recognized by the Pennsylvania Life Sciences Awards Program as a CEO of the Year.
July 14, 2010
Vitae Pharmaceuticals Hires Christine Brennan, Ph.D. as Chief Business Officer
November 11, 2009
Vitae Pharmaceuticals to Present at Windhover's Annual Therapeutic Area Partnerships Conference
September 29, 2009
Vitae Pharmaceuticals Receives $8 Million Payment from Boehringer Ingelheim for Achievement of 11beta-HSD-1 Program Milestone
October 28, 2008
Vitae Pharmaceuticals Secures $13 Million In Debt Financing
March 5, 2008
Vitae Pharmaceuticals Appoints Richard Gregg, M.D. as Chief Scientific Officer